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Abstract
Background: Copy number polymorphisms caused by genomic rearrangements like deletions,
make a significant contribution to the genomic differences between two individuals and may add to
disease predisposition. Therefore, genotyping of such deletion polymorphisms in case-control
studies could give important insights into risk associations.
Results: We mapped the breakpoints and developed a fluorescent fragment analysis for a deletion
disrupting the TRY6 gene to exemplify a quick and cheap genotyping approach for such structural
variants. We showed that the deletion is larger than predicted and encompasses also the
pseudogene TRY5. We performed a case-control study to test an association of the TRY6 deletion
polymorphism with breast cancer using a single nucleotide polymorphism which is in 100% linkage
disequilibrium with the deletion. We did not observe an effect of the deletion on breast cancer risk
(OR 1.05, 95% CI 0.71–1.56).
Conclusion:  Although we did not observe an association between the TRY6  deletion
polymorphism and breast cancer risk, the identification and investigation of further deletions using
the present approach may help to elucidate their effect on disease susceptibility.
Background
An unexpectedly large amount of structural variation in
the human genome has recently become apparent [1]. The
identification of genomic deletions, insertions and inver-
sions, ranging from 1 kb to several Mb in size, has broad-
ened our knowledge about genetic variation between
individuals, which may lead to new insights into pheno-
typic variation and clinical outcome [2]. The rearrange-
ments can encompass exons or even entire genes and their
regulatory regions. Such structural variants, called copy
number polymorphisms (CNPs), have been identified by
array-based methods [3-6]. Interestingly, a high percent-
age of copy number variants has been found to be in close
proximity to segmental duplications, suggesting a recom-
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bination mechanism between the repetitive sequences
[4,7,8]. Owing to the high sequence similarity between
duplications and their consequent high recombination
potential, segmental duplications are frequently found at
breakpoints of both disease-associated and evolutionary
rearrangements [9]. The HapMap data on family trios
have been used to identify CNPs [10,11]. As deletions
normally are not detected by standard single nucleotide
polymorphism (SNP) genotyping methods, hemizygotes
are usually misclassified as homozygotes. When a dele-
tion is transmitted from parent to offspring, the child will
show a null genotype or a genotype violating the rules of
mendelian inheritance [10]. However, the exact borders
of the structural variants still remain to be ascertained,
which makes it difficult to perform high-throughput gen-
otyping of CNPs. Furthermore, linkage disequilibrium
(LD) between deletions and SNPs has been demonstrated
[11,12], suggesting that these variants show a similar evo-
lutionary history [12]. The use of SNP genotyping may
also be an alternative for the genotyping of the deletions.
However, recent reports have raised concern over the use
of SNPs as surrogates for CNPs in structurally dynamic
regions [7,13].
As CNPs contribute to the genetic variability between two
individuals, the identification of their influence on dis-
ease association remains a great challenge. We developed
a simple PCR-based assay to genotype exemplarily a com-
mon deletion polymorphism encompassing the trypsino-
gen C (TRY6) gene [11,14]. TRY6 is a member of a highly
homologous serine protease family (PRSS) which com-
prises the active trypsinogen genes 1 (alias PRSS1, TRY1 or
T4), 2 (alias PRSS2, TRY2 or T8) and 4 (alias PRSS3, TRY4
or T9), the transcribed pseudogene TRY6 and the pseudo-
genes  TRY5  and  TRY7. These genes cluster within the
human T cell receptor (TCR) locus on chromosome 7
(Figure 1A) [14]. They exhibit ~91% overall similarity at
both nucleotide and protein levels and harbour numerous
interspersed repeats. The trypsinogen locus is of dynamic
nature. It has been shown that, in the course of evolution,
PRSS3 has duplicated and translocated from chromosome
7 to chromosome 9. Thus, the locus may be a subject of
frequent recombination events. Trypsinogens are the pre-
cursors of the serine protease trypsin that has been linked
to tumour progression in colorectal cancer through activa-
tion of matrix metalloproteinases, which degrade extracel-
lular matrix components [15]. Additionally, TRY6 has
been shown to be overexpressed in metastasising non-
small cell lung tumours, correlating with survival [16].
We present an approach to specify the breakpoints of the
common deletion polymorphism encompassing the
TRY6 gene and then describe a genotyping assay, using
fluorescent multiplex PCR, to investigate whether the
deletion is associated with breast cancer risk. Alterna-
tively, the deletion can be genotyped by analysing a neigh-
bouring SNP which is in 100% LD with the deletion
polymorphism. These methods can be adapted for other
deletion polymorphisms.
Results
Identification of TRY6 breakpoints
The TRY 6 deletion has been described by McCarroll et al.
to range at least from 142,160,877 to 142,170,663 on
chromosome 7 (NCBI build 36), spanning a minimum
region of 9786 bp [11]. We designed primers that flank
the breakpoints of the predicted deletion (fragments 2
and 8, Figure 1B) and primers within the deletion (frag-
ments 3 and 7) to confirm the known homozygous carri-
ers among the CEPH individuals. Homozygotes for the
deletion should not give a PCR product within the deleted
region. Additionally, we used primers for an independent
gene fragment (growth hormone releasing hormone,
GHRH) to show that the samples could be amplified. No
PCR products were observed for the fragments 2, 3, 7 and
8 in samples from the homozygous individuals, indicat-
ing that the deletion was longer than predicted. We
designed new primers outwards in intervals of 1.5–2 kb.
For homozygous samples, we did not obtain a PCR prod-
uct until the fragments 4 and 11 (Figure 1B). To map the
breakpoints, we designed primers surrounding the pre-
sumed region and covering the complete region between
fragments 4 to 5 and 10 to 11, respectively (Figure 1C).
The deleted region mapped between nucleotides
142,155,045 and 142,175,904 (Figure 2). Sequencing of
a homozygous sample showed a sequence as outlined in
Figure 2. The region is flanked by two 484 bp long
sequences that differ in only one nucleotide (T/G) after
the first 222 bp. In the homozygous samples this
sequence was present only once, suggesting that the dele-
tion is a result of a non-allelic homologous recombina-
tion between these two sequences. Furthermore, we
identified two discrepancies to the published sequence in
the NCBI database (NT_007914.14, Build 36) by compar-
ing the sequences of the full-length and the deletion-con-
taining samples. At 142,155,267, a T instead of the
reported G constitutes the wild type sequence and at
142,175,643 a G is present instead of the reported T. Since
the sequences are nearly 100% identical, these initial
sequencing errors could be due to unspecific primers; and
both positions are reported to be polymorphic
(rs4019213 and rs2734212, respectively). Search with the
RepeatMasker database revealed no retroviral elements
within the breakpoint region. In contrast to the reported
10 kb size of the deletion, we enlarged the disrupted
region to about 20.6 kb.
Fragment analysis for a case-control study
In order to genotype the deletion in a high-throughput
process, we developed a fluorescent fragment analysisBMC Genetics 2007, 8:41 http://www.biomedcentral.com/1471-2156/8/41
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assay using a triplex PCR with FAM-labelled reverse prim-
ers. The forward primer was located 5' to the breakpoint
(primer 4F), the reverse primer for detecting the wild type
allele within the deletion sequence (primer 4aR) and the
reverse primer for detecting the deletion 3' to the break-
point (primer 10aR) (Figure 3). This enabled us to specif-
ically amplify both the wild type and the deletion alleles,
even in heterozygous samples. The high sequence hom-
ology within the trypsinogen gene cluster and the length
of the repeat sequence at the breakpoints (484 bp) limited
the options for primer selection, thus the resulting specific
fragments for the wild type and the deletion alleles were
778 bp and 893 bp, respectively. Since these fragments
were too large to run on the Genetic Analyzer efficiently,
we digested the PCR product with SchI. The resulting frag-
ments of 186 bp and 301 bp were visualised after the frag-
ment analysis run (Figure 4) and called automatically by
the GeneMapper software.
rs13230029 is not associated with breast cancer risk
Common deletions and nearby SNPs have been shown to
be in strong LD [11,12]. We screened several SNPs sur-
rounding the deletion as described by McCarroll et al. [11]
in a small set of 23 samples in order to confirm the LD
between the SNPs and the deletion. We chose a SNP 8240
bp upstream of the deleted region (rs13230029, Figure
1A) to perform a case-control study with 397 Polish famil-
ial and early age breast cancer cases and 454 regionally
and ethnically matched unrelated female controls using
TaqMan allelic discrimination. The genotype distribution
(A) Schematic organisation of the human T-cell receptor locus on chromosome 7 containing the trypsinogen genes PRSS1,  PRSS2 and TRY6 and the pseudogenes TRY5 and TRY7 Figure 1
(A) Schematic organisation of the human T-cell receptor locus on chromosome 7 containing the trypsinogen genes PRSS1, 
PRSS2 and TRY6 and the pseudogenes TRY5 and TRY7. The figure is not drawn to scale. Numbering according to 
NT_007914.14, NCBI build 36. (B) Magnification of the region investigated to map the breakpoints. The PCR fragments used 
to map the deletion are numbered 1–13, corresponding to the primer pairs shown in Table 1. The fragments for which a PCR 
product was obtained in the samples homozygous for the deletion is indicated with X; – indicates no PCR product in the 
homozygote samples. The deletion reported by McCaroll et al. [11] is indicated as well as the revised deletion size. (C) Fine-
scaling of the breakpoints and cut-out of the fragments used to narrow down the breakpoint region. The breakpoints are 
marked with a red circle.
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Sequence alignment of the deletion-specific TRY6 PCR product (generated with 4F and 10aR primers) sequence and the  respective 5' and 3' sequences of the full-length TRY6 Figure 2
Sequence alignment of the deletion-specific TRY6 PCR product (generated with 4F and 10aR primers) sequence and the 
respective 5' and 3' sequences of the full-length TRY6. The 5' and 3' TRY6 sequences were derived from Genbank 
NT_007914.14 (NCBI Build 36). PCR primer sequences are underlined. Letters in black indicate identity, letters in red indicate 
mismatches; points (·) underscore the homologous deletion breakpoint region. * shows the position of discrepancy between 
our sequencing results and the GenBank sequence (NT_007914.14)
142,154,911 ATTGATCTTGTCATGTGGAATTTGAGAGATCTAGAAGCCCCACAGCAACCTACCATACAA  5’sequence 
              TTGAGAGATCTAGAAGCCCCACAGCAACCTACCATACAA  del PCR product 
142,175,287 ATTGATCTTGTCACCTGGAATTTGAGAGATCAAGAAGCCCCATAGCAACCTACCATACAA 3’  sequence 
142,154,971 CTGCCTATCAGCGCTCATCCTTTCACAGGATTAGCTCAATTCTGGCTCTGCAGACACTGG  5’sequence 
           CTGCCTATCAGCGCTCATCCTTTCACAGGATTAGCTCAATTCTGGCTCTGCAGACACTGG  del PCR product 
142,175,347    CTGCCCATCAGCGCTCATCCTTTCACAGGATTAGCTCAATTCTGACTCTGCAGACACTGG 3’  sequence 
142,155,031 CAGCCACGGGTGAGAAACCCTGGGCCTCTGTGGGCTTCCTTCATCACCCAGGGCCACAGT  5’sequence 
CAGCCACGGGTGAGAAACCCTGGGCCTCTGTGGGCTTCCTTCATCACCCAGGGCCACAGT   del PCR product 
142,175,407 CAGCCACAGGTGACAAACCCTGGGCCTCTGTGGGCTTCCTTCATCACCCAGGGCCACAGT 3’  sequence 
142,155,091 GGGCTGCCTGTCCTAGGCAGAGACACAGCAACATTCTCTTAAGCTGAAATTAAGCATAAA  5’sequence 
GGGCTGCCTGTCCTAGGCAGAGACACAGCAACATTCTCTTAAGCTGAAATTAAGCATAAA  del PCR product 
142,175,467 GGGCTGCCTGTCCTAGGCAGAGACACAGCAACATTCTCTTAAGCTGAAATTAAGCATAAA   3’ sequence 
142,155,151 CCCACTTCACCAATAATCATCTGAGGGCACAGTCCCTGCCTCCTTCCTTGGGGATTTTAA  5’sequence 
CCCACTTCACCAATAATCATCTGAGGGCACAGTCCCTGCCTCCTTCCTTGGGGATTTTAA   del PCR product 
142,175,527 CCCACTTCACCAATAATCATCTGAGGGCACAGTCCCTGCCTCCTTCCTTGGGGATTTTAA 3’  sequence 
                                    
142,155,211 AACACACATCTCTCTGACCAAACAGGTAGGTGAGATCTGACTTTAAAGGGGGGAAATTGG 5’sequence 
    AACACACATCTCTCTGACCAAACAGGTAGGTGAGATCTGACTTTAAAGGGGGGAAAGTGG   del PCR product 
142,175,587 AACACACATCTCTCTGACCAAACAGGTAGGTGAGATCTGACTTTAAAGGGGGGAAAGTGG  3’ sequence   
                                                                       * 
142,155,271 GATGAATTGGGGTATCAGGAATGAATCCCAAGTGTTTTTGTGTGGCGAATGGCATCCACA  5’sequence 
    GATGAATTGGGGTATCAGGAATGAATCCCAAGTGTTTTTGTGTGGCGAATGGCATCCACA   del PCR product 
142,175,647 GATGAATTGGGGTATCAGGAATGAATCCCAAGTGTTTTTGTGTGGCGAATGGCATCCACA 3’  sequence 
142,155,331 TCCCAAAATATACTTGGAGATGGGGAAAAAAGCAGGAGAGGAGAAGGGTAAAAAAGGAGG  5’sequence 
    TCCCAAAATATACTTGGAGATGGGGAAAAAAGCAGGAGAGGAGAAGGGTAAAAAAGGAGG   del PCR product 
142,175,707 TCCCAAAATATACTTGGAGATGGGGAAAAAAGCAGGAGAGGAGAAGGGTAAAAAAGGAGG 3’  sequence 
142,155,391 ACAAAGTGTCTGAAAGTCATTGAAAGCTTCTCTCATGGTTCTTTCTGGCTCTGGTTGCTT  5’sequence 
ACAAAGTGTCTGAAAGTCATTGAAAGCTTCTCTCATGGTTCTTTCTGGCTCTGGTTGCTT   del PCR product 
142,175,767 ACAAAGTGTCTGAAAGTCATTGAAAGCTTCTCTCATGGTTCTTTCTGGCTCTGGTTGCTT 3’  sequence 
142,155,451 TGCCAAGGTCTTGAGTGCAGGCAGGGCTGGCTCTGGCTGGGAGCTGCTGCTCTGGAACAT  5’sequence 
TGCCAAGGTCTTGAGTGCAGGCAGGGCTGGCTCTGGCTGGGAGCTGCTGCTCTGGAACAT  del PCR product 
142,175,827 TGCCAAGGTCTTGAGTGCAGGCAGGGCTGGCTCTGGCTGGGAGCTGCTGCTCTGGAACAT 3’  sequence 
142,155,511 GGAAGAGTCACTTCACCTCCAGAAAGCTCATTTGATCATCTGTAAAATGGGCAAGCCCAT 5’sequence 
GGAAGAGTCACTTCACCTTCAGAAAGCTCATTTGCTCATCTGTAAAGTGGGCAATTCCAT  del PCR product 
142,175,887 GGAAGAGTCACTTCACCTTCAGAAAGCTCATTTGCTCATCTGTAAAGTGGGCAATTCCAT 3’  sequence 
142,155,571 AGGTGGTTGTGATGACAAAATGAAAAAAACTTTCTTAACTTACATGAGTGACATGCTGTA 5’sequence 
AGGTGGTTGTGATGATAAAATGAAAAAAAAGTTCTTAACTTATATGAGTGACATGCTGTA  del PCR product 
142,175,947 AGGTGGTTGTGATGATAAAATGAAAAAAAAGTTCTTAACTTATATGAGTGACATGCTGTA  3’  sequence 
142,155,631 TAGTAAGTTACATGC-TATATAGGAAGCACACAGAAATAATTCACTGTTATCATAAATGA 5’sequence 
  TAGTAAGTTACATGCCTATATAGGAAGCACACAGAAATGATTCACTGTTATGATAATGGA  del  PCR  product 
142,176,007 TAGTAAGTTACATGCCTATATAGGAAGCACACAGAAATGATTCACTGTTATGATAATGGA  3’  sequence 
142,155,691 AACACAGTGGATTAGTGAGCTAAGCACTAAATGGAAGCCAGAAAGATGTCT-AGAGAAGT 5’sequence 
  AGGACAGTGGTTTGGCATGTTAAGCACTAAACAGAAGCCAGAAAGATATCTTAGAGAAGT  del  PCR  product 
142,176,067 AGGACAGTGGTTTGGCATGTTAAGCACTAAACAGAAGCCAGAAAGATATCTTAGAGAAGT  3’  sequence 
142,155,751 AGACAAAGAAATCTATAGTTCAGAATGAACAGTATCAAGAATGACATGTCCTCCAAATTG 5’sequence 
  AGACAAAGAAATCTATAGTTCAGAATGAACAGTACCAAGAATGACATGTCCCCCAAATTG  del PCR product 
142,176,127 AGACAAAGAAATCTATAGTTCAGAATGAACAGTACCAAGAATGACATGTCCCCCAAATTG  3’  sequence 
142,155,811 AGCTTGGGCAGCTGGATCTGAACCTATCCTACACATCTGAGTCTACAGTATGAGGTAACA 5’sequence 
  AGCATGGGTAGCTG         del  PCR  product 
142,176,187 AGCATGGGTAGCTGGATCTGAACCTATCCTACACATCTGAGTCTACAGTATGAGGTAACA  3’  sequence BMC Genetics 2007, 8:41 http://www.biomedcentral.com/1471-2156/8/41
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followed Hardy-Weinberg equilibrium. There were no dif-
ferences in the allele and genotype frequencies between
the cases and the controls (Table 2). We carried out a frag-
ment analysis on 200 samples and confirmed that the
SNP was completely linked with the deletion. We con-
clude that the deletion polymorphism of TRY6 is not asso-
ciated with breast cancer risk.
Discussion
Large genomic variations show a potential at least as great
as SNPs to have an impact on disease susceptibility, given
that regulatory regions, exons and even whole genes can
be deleted, duplicated or disrupted [2]. Deletions result
from non-allelic homologous recombination events that
occur between blocks of duplicated sequences [4,7].
Recent studies have provided a preliminary characterisa-
tion of deletions and paved the way to disease association
studies [3-6,10-12]. However, fast, cheap and reliable
techniques are needed to perform case-control studies for
the identification of disease correlation.
Real-time PCR can be used for the detection of individual
deletions or duplications but it is not appropriate for mul-
tiplexing [2]. Furthermore, the optimisation process takes
time and the throughput is limited. For the amplification
of multiple regions, quantitative multiplex PCR of short
fluorescent fragments (QMPSF), multiplex amplifiable
probe hybridisation (MAPH) and multiplex ligation-
dependent probe amplification (MLPA) are more ade-
quate [2]. However, MAPH and MLPA require several han-
(A) Schematic diagram of the TRY6 deletion and the location of the primers used for fluorescent fragment analysis Figure 3
(A) Schematic diagram of the TRY6 deletion and the location of the primers used for fluorescent fragment analysis. (B) PCR 
products amplified by multiplex PCR. (C) PCR products created for fluorescent fragment analysis by SchI digestion.
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An example of the fragment analysis results using the GeneMapper 4 software Figure 4
An example of the fragment analysis results using the GeneMapper 4 software. (A) A homozygous sample for the wild type 
allele, 186 bp. (B) A homozygous sample for the deletion allele, 301 bp. (C) A heterozygous samples, 186 bp + 301 bp.
del
het
186 bp                                               301 bp
A
B
C
wtBMC Genetics 2007, 8:41 http://www.biomedcentral.com/1471-2156/8/41
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dling steps, the commercially available kits are still
expensive and pre-designed for only common sites and
these methods are not suitable for the identification of
heterozygous genotypes. QMPSF is a faster method, yet
the optimisation, especially for heterozygotes, is time-
consuming and tedious and one should have control sam-
ples with known genotypes for comparison of the results.
All the above described methods could be useful for iden-
tifying breakpoints in homozygous samples where it is
only important to know if the product is present or
absent. A quicker and safer approach is a triplex PCR using
primers that flank the deletion break points, as described
here and elsewhere [3,17,18]. If the primers are labelled
fluorescently, an automatic analysis ensures a fast evalua-
tion of the results. However, it is essential to know the
deletion borders to design the primers.
We refined the borders of the deletion by amplifying short
fragments in intervals of 1500–2000 bp throughout the
predicted and the extended region of the TRY6 gene dele-
tion polymorphism in individuals with known
homozygous genotypes obtained from the HapMap sub-
Table 1: Primer sequences used to map the breakpoints.
Primer combination Primer sequence Product size (bp)
1F/R* F: GAC ACA AAG ACG TGG GAG TC
R: GAG GCA GCC TGG CTG GGA
384
2F/R* F: GTG AAA GAG GCT GGG AAG GTG
R: CCC TTC TTT CAC AGC TGG GGC
249
3F/R* F: ACA GGT GAT AAA AGC CCG AGC C
R: GCC CTC AGA TGA TTA TTG GTG AAG T
144
4F†/R F: TTG AGA GAT CTA GAA GCC CCA C
R: GCC CTC AGA TGA TTA TTG GTG AAG T
247
5F/R* F: TAA GTC TCC TTT TAG ATG CCA CC
R: GGA GTT TTC ATG TAA GCA GCA GTG
261
6F/R* F: CTC CAG AGC TAT AAA GAC GGG C
R: CGG CAG GGC ATA TGT CTG CCA
159
7F/R* F: AAA AGA GAG AAG CAT TCA GTG GG
R: CGG TTG CTT CCT GCT AAT TAG AA
261
8F/R* F: GAA TGA ACA GTT CAT CTA TGC G
R: CGG TGT GCT TCG TTC TGG AAA T
272
9F/R* F: TCT GAG GGC TGT GAC ACC ATG
R: GAC ACA GGT GAC ATG AAG CCT G
100
10F/R F: CTG GGA AAG GAT CCC TCA AG
R: GTC AAC TGT GGC TGC CAG TG
160
11F/R F: ACA TGT TCA GGG ACA ACA CAG C
R: CAC ACC TCT CTG CTC ATG AAT AA
97
12F/R F: AAC TCT GAC ATG TGA TCA GGG G
R: CAT GTG CAT CCT GTC ATA GGT TC
143
13F/R F: AAG CAG CCA CAG GCT GGG AGC
R: CCT GGC TGG GAG TTT TGC AGT
273
4aF/R† F: GAT GAA TTG GGG TAT CAG GAA TG
R: GCT CAC TAA TCC ACT GTG TTT CAT
437
4bF/R* F: CTG TGA TTG TTT AAG GAA GAG CG
R: CAC AAC TCT CTG CTC ACA GAT AA
380
10aF/R† F: CCC AAG TGT TTT TGT GTG GCG AAT GG
R: CAG CTA CCC ATG CTC AAT TTG G
530
10bF/R F: GGA AGG ACA GTG GTT TGG CAT G
R: GTC AAC TGT GGC TGC CAG TG
620
* fragment is within the deletion region
† primers used for triplex PCR
Table 2: Allele and genotype frequencies, odds ratios, 95% confidence intervals and p-values for the SNP rs13230029.
rs13230029 Cases (%) Controls (%) OR (95% CI) p-value
CC 136 (0.34) 159 (0.35) 1
CG 190 (0.48) 216 (0.48) 1.03 (0.76–1.39) 0.86
GG 71 (0.18) 79 (0.17) 1.05 (0.71–1.56) 0.81
G% 0.42 0.41BMC Genetics 2007, 8:41 http://www.biomedcentral.com/1471-2156/8/41
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jects [11]. Homozygote carriers showed the absence of the
PCR products, while the fragments were present in the
wild type and the heterozygote samples. As an internal
control for the sample quality, we simultaneously ampli-
fied a fragment of an independent gene. We mapped the
breakpoints by sequencing the complete region between
the two fragments flanking the deletion in the
homozygous samples and by comparing the obtained
sequence to the published one (NT_007914.14, NCBI
Build 36). A triplex PCR with primers neighbouring the
borders enabled discrimination between the three geno-
types. Due to the fluorescence of the reverse primer, the
products could be visualised on a sequencer and analysed
automatically with the appropriate software. This method
is fast, cheap (0.70€/genotype) and easy to perform.
TRY 6 is deleted in a common polymorphism [11,14].
Although this locus appears to encode a protein similar to
trypsinogen, the locus is thought to be a transcribed pseu-
dogene [19]. ESTs support its transcription, but expres-
sion of its predicted protein has not been observed. The
predicted protein sequence of TRY 6 differs significantly
from the known functional trypsinogens, including a dif-
ferent amino acid at the conserved residue 122 which is
important for autolysis. However, it has been suggested
that it is expressed in minute amounts in the thymus [14].
A recent study has identified TRY6 to be up-regulated in
metastatic non-small cell lung cancer leading to an
enhanced cell migration [16]. Patients with high expres-
sion of TRY6 also had a substantially worse prognosis
than patients without TRY6 expression. We picked this
deletion polymorphism to test our method because it was
shown to be real, frequent and affecting the coding region
[11]. We did not find an association of the TRY6 deletion
with breast cancer susceptibility. With our sample size,
considering that the cases had familial or early onset
breast cancer and that ~17% of the controls were
homozygous for the deletion, we had an >80% power to
detect an OR of 0.6. Thus, we can only exclude a major to
moderate effect of the TRY6 deletion on breast cancer risk.
The negative findings of our study may be explained by
the fact that TRY6, and the deleted neighbouring gene,
TRY5, are pseudogenes. Although TRY6 mRNA expression
has been established, the function of the gene remains to
be clarified.
Several reports have shown that deletion polymorphisms
show strong LD with common SNPs [11,12,18]. We gen-
otyped a SNP and confirmed its LD with the deletion.
Genotyping a SNP is faster and cheaper than detecting the
structural variant. However, recent studies have found
only modest evidence of LD between CNPs and HapMap
SNPs, suggesting that duplication rich regions are not suit-
able for the identification of linked SNPs due to technical
restrictions [7,13]. This raises the concern that several
genomic regions most prone to rearrangements have
inadequate SNP density to successfully map CNPs with
the use of available SNP markers. Thus, additional meth-
ods, such as the fluorescent fragment analysis for deletion
polymorphisms described by us, are needed to reliably
genotype CNPs.
The comparability of the results generated from various
array-based studies is currently the major obstacle in the
field, contributing to confusion in data interpretation
between different reports. Because accurate genotyping
requires exact sequence data, refining the deletion break-
points should rank first. Furthermore, the mapping of
CNP breakpoints will also enable the identification of
nearby SNPs, which would be in LD with the deletion.
Thus, the description of all variants will help to design
studies relating to disease, pharmacogenomics and clini-
cal practice. They can be searched in the Database of
Genomics Variants [20], which is regularly updated with
the latest detected CNPs. The development of methods to
identify other subtle variations such as inversions or inser-
tions still remains a challenge.
We presented a simple high-throughput approach to gen-
otype common deletion polymorphisms. Although we
did not observe an association between the TRY6 deletion
polymorphism and breast cancer risk, the identification
and investigation of further deletions using the present
approach may help to elucidate their effect on disease sus-
ceptibility.
Methods
Breakpoint mapping
Based on the analysis carried out on the Hapmap samples
by McCarroll et al. [11,21], we selected CEPH individuals
homozygous for the TRY6  deletion polymorphism to
define the breakpoints of the deletion. We amplified sev-
eral fragments throughout the TRY6 gene region (Figure
1B). The fragments were first limited to the predicted
region but then extended outwards on both directions.
Homozygotes for the deletion should not give a PCR
product within the deleted region, which was used in
mapping the breakpoint. The primer sequences and prod-
uct sizes are listed in Table 1. Amplification was per-
formed with 5 ng genomic DNA in a 10 μl reaction
volume using 1× PCR buffer, 1.5 mM MgCl2, 0.11 μM
dNTP Mixture (Invitrogen, Paisley, UK), 0.15 μM of each
primer (Thermo Electron Corporation, Ulm, Germany)
and 0.3 U PlatinumTaq Polymerase (Invitrogen). The PCR
was carried out in a GeneAmp 9700 PCR system (Applied
Biosystems, Foster City, USA) using 94°C for 2 min, fol-
lowed by 3 cycles of 94°C for 1 min, 67°C for 1 min and
72°C for 1 min and 32 cycles of 94°C for 30 s, 66°C for
30 s and 72°C for 30 s. The final extension was performedBMC Genetics 2007, 8:41 http://www.biomedcentral.com/1471-2156/8/41
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for 6 min at 72°C. The PCR products were visualised on
1.5% agarose gels stained with ethidium bromide.
DNA sequencing
The PCR product was cleaned-up using 0.75 μl ExoSapIT
(USB Amersham, Uppsala, Sweden) for 40 min at 37°C
followed by 15 min at 85°C. The sequencing reaction was
carried out using the BigDye Terminator Cycle Sequencing
Ready Reaction Kit (Applied Biosystems) on the Genetic
Analyzer 3130XL as described earlier[22] The original
data was analysed by the Sequencing Analysis 5.2 and
DNASTAR Lasergene 5.0 (DNASTAR Inc., Madison, USA)
softwares.
Sequence alignment
The sequence of a sample with a homozygous deletion
was aligned to the sequence surrounding the observed
breakpoint on both sides. The reference sequence was
derived from Genbank NT_007914.14, NCBI build 36.
The alignment (Figure 2) was performed using MegAlign
5.05 (DNAStar Inc., USA).
Subjects
The analysis of the TRY6  deletion was performed on
genomic DNA from 397 Polish familial and early age
breast cancer cases (mean age 46 years, range 26–81) and
454 regionally and ethnically matched unrelated female
controls (mean age 42 years, range 16–79). The inclusion
criteria for the cases were (i) at least 2 first-degree relatives
with breast and/or ovarian cancer regardless of age, (ii)
breast cancer diagnosed below the age of 35 without fam-
ily history, (iii) bilateral breast cancer regardless of the
family history, (iv) breast and ovarian cancer diagnosed in
one patient regardless of the family history and (v) breast
cancer diagnosed below 50 years of age regardless of fam-
ily history[23] The subjects corresponding to criteria (i)-
(iv), 215 cases, were collected during the years 1997 to
2002 by the Chemotherapy Clinics and the Genetic Coun-
selling Service (Gliwice, Poland) and the subjects corre-
sponding to criteria (v), 182 cases, were collected during
the time period December 2002 to March 2004 by the
Surgery Clinics (Gliwice, Poland). The cases were tested
for four founder mutations in BRCA1 and two in BRCA2,
which account for ~90% of the mutations in the Polish
population, and found to be negative [24]. We included
familial and early onset cases to our study because it has
been shown that selection of cases based on the family
history increases the power to detect low-penetrance vari-
ants [25,26]. The study was approved by the ethical com-
mittee of the University of Heidelberg.
Fluorescent fragment analysis
In order to genotype individuals for the deletion polymor-
phism (Figure 3), we used a triplex PCR with the primers
4F, 4aR and 10aR (Table 1). The reverse primers were
labelled with 6-FAM (Invitrogen). We performed the
amplification with the conditions mentioned above. The
resulting product was digested with 4 U SchI (Fermentas,
St. Leon-Roth, Germany) for 4 h at 37°C. 1 μl of the diges-
tion product was added to 10 μl HIDI-Formamide/GeneS-
can ROX350 standard size marker (mixed according to the
manufacturer's instruction, Applied Biosystems). The
mixture was denatured for 5 min at 95°C, loaded onto the
ABI PRISM 3130XL Genetic Analyser and analysed by the
GeneMapper software version 4.0 (Applied Biosystems).
TaqMan analysis
The TaqMan assay for SNP rs13230029 was obtained as
custom assay from Applied Biosystems and the assay
details are available on request. The reaction was per-
formed in 5 μl using 5 ng of genomic DNA, 1× TaqMan
Universal Master Mix (Applied Biosystems) and 0.6×
Assay-Mix (40×) per reaction. PCR was performed at 50°C
for 2 min, 95°C for 10 min and 35–45 cycles at 92°C for
15 s and 60°C for 1 min. PCR was performed in a Gene-
Amp PCR System 9700 thermocycler and the number of
cycles was dependent on the genotype clustering. The
samples were read and analysed in an ABI Prism 7900 HT
sequence detection system using the SDS 1.2 software
(Applied Biosystems).
Statistical analysis
The observed genotype frequencies in the breast cancer
cases and controls were tested for Hardy-Weinberg equi-
librium (HWE) and the difference between the observed
and expected frequencies was tested for significance using
the χ2-test. Odds ratios (ORs) and 95% confidence inter-
vals (95% CIs) were calculated for associations between
genotypes and breast cancer. The calculations were carried
out using the HWE test tool offered by the Institute of
Human Genetics, TU Munich [27]. Power calculation was
carried out using the PS software for power and sample
size calculation [28,29].
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